Role of the STK15 Phe31Ile polymorphism in renal cell carcinoma

Oncology Reports

Volumn 17, Issue 1, 2007, Pages 3-7

  Hammerschmied, Christine G ^a   Stoehr, Robert ^a   Walter, Bernhard ^a   Wieland, Wolf F ^a   Hartmann, Arndt ^a   Blaszyk, Hagen ^b   Denzinger, Stefan ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

ARK1; Aurora 2; Aurora A; BTAK; PCR; Renal cell carcinoma; Restriction fragment length polymorphism; Single nucleotide polymorphism; STK15

Indexed keywords

AURKA PROTEIN, HUMAN; ISOLEUCINE; PHENYLALANINE; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CANCER STAGING; CASE CONTROL STUDY; ENZYMOLOGY; GENETICS; GENOTYPE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; ISOLEUCINE; KIDNEY NEOPLASMS; NEOPLASM STAGING; PHENYLALANINE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES;

EID: 39049195814     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.1.3     Document Type: Article

References (46)

1. Atzpodien J, Kirchner H, Jonas U, et al: Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22: 1188-1194, 2004. (Pubitemid 41079830)
2. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338: 1272-1278, 1998. (Pubitemid 28216581)
3. Ljungberg B: Prognostic factors in renal cell carcinoma. Urologe A 43 (Suppl 3): 119-120, 2004.
4. Grignon DJ, Eble JN, Bonsib SN, et al: Tumours of the kidney. In: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Eble JN, Sauter G, Epstein JI and Setershenn IA (eds). IARC Press, Lyon, pp10-34, 2004.
5. Bugert P, Gaul C, Weber K, Herbers J, Akhtar M, Ljungberg B and Kovacs G: Specific genetic changes of diagnostic importance in chromophobe renal cell carcinomas. Lab Invest 76: 203-208, 1997. (Pubitemid 27082063)
6. Kovacs G: Molecular differential pathology of renal cell tumours. Histopathology 22: 1-8, 1993.
7. Kovacs G, Szucs S, De Riese W and Baumgartel H: Specific chromosome aberration in human renal cell carcinoma. Int J Cancer 40: 171-178, 1987. (Pubitemid 17126125)
8. Palmedo G, Fischer J and Kovacs G: Fluorescent microsatellite analysis reveals duplication of specific chromosomal regions in papillary renal cell tumors. Lab Invest 77: 633-638, 1997. (Pubitemid 28018784)
9. Speicher MR, Schoell B, Du Manoir S, et al: Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 145: 356-364, 1994. (Pubitemid 24245836)
10. Sanjmyatav J, Schubert J and Junker K: Comparative study of renal cell carcinoma by CGH, multicolor-FISH and conventional cytogenic banding analysis. Oncol Rep 14: 1183-1187, 2005.
11. Junker K, Moravek P, Podhola M, Weirich G, Hindermann W, Janitzky V and Schubert J: Genetic alterations in metastatic renal cell carcinoma detected by comparative genomic hybridization: correlation with clinical and histological data. Int J Oncol 17: 903-908, 2000.
12. Katayama H, Brinkley WR and Sen S: The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22: 451-464, 2003. (Pubitemid 36791899)
13. Adams RR, Carmena M and Earnshaw WC: Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 11: 49-54, 2001. (Pubitemid 32144751)
14. Dutertre S, Descamps S and Prigent C: On the role of aurora-A in centrosome function. Oncogene 21: 6175-6183, 2002.
15. Ewart-Toland A, Dai Q, Gao YT, et al: Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 26: 1368-1373, 2005. (Pubitemid 41417879)
16. Miyoshi Y, Iwao K, Egawa C and Noguchi S: Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92: 370-373, 2001. (Pubitemid 32249713)
17. Sen S, Zhou H, Zhang RD, et al: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94: 1320-1329, 2002.
18. Jeng YM, Peng SY, Lin CY and Hsu HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10: 2065-2071, 2004.
19. Tong T, Zhong Y, Kong J, et al: Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 10: 7304-7310, 2004. (Pubitemid 39487719)
20. Ehara H, Yokoi S, Tamaki M, et al: Expression of mitotic Aurora/Ipl1p-related kinases in renal cell carcinomas: an immunohistochemical study. Urol Res 31: 382-386, 2003. (Pubitemid 38004923)
21. Erichsen HC and Chanock SJ: SNPs in cancer research and treatment. Br J Cancer 90: 747-751, 2004. (Pubitemid 38406580)
22. Ewart-Toland A, Briassouli P, De Koning JP, et al: Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34: 403-412, 2003. (Pubitemid 36935333)
23. Dai Q, Cai QY, Shu XO, et al: Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 13: 2065-2070, 2004. (Pubitemid 40054299)
24. Dicioccio RA, Song H, Waterfall C, et al: STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 13: 1589-1594, 2004. (Pubitemid 39331879)
25. Sobin LH and Wittekind C: TNM classification of malignant tumors. Wiley & Sons, 2002.
26. Greene LF PD, Fleming D, Firtz A, Batch M, Haller DG and Morrow M: American Joint Committee on Cancer (AJCC). Cancer Staging Manual. Springer-Verlag, 2002.
27. Stoehr R, Krieg RC, Knuechel R, et al: No evidence for involvement of beta-catenin and APC in urothelial carcinomas. Int J Oncol 20: 905-911, 2002.
28. Kovacs A, Storkel S, Thoenes W and Kovacs G: Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas. J Pathol 167: 273-277, 1992.
29. Kovacs G and Frisch S: Clonal chromosome abnormalities in tumor cells from patients with sporadic renal cell carcinomas. Cancer Res 49: 651-659, 1989. (Pubitemid 19050331)
30. Fraizer GC, Diaz MF, Lee IL, Grossman HB and Sen S: Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25: 1631-1639, 2004.
31. Yamamoto Y, Matsuyama H, Kawauchi S, et al: Biological characteristics in bladder cancer depend on the type of genetic instability. Clin Cancer Res 12: 2752-2758, 2006.
32. Zhou H, Kuang J, Zhong L, et al: Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20: 189-193, 1998. (Pubitemid 28455454)
33. Kiat LS, Hui KM and Gopalan G: Aurora-A kinase interacting protein (AIP), a novel negative regulator of human Aurora-A kinase. J Biol Chem 277: 45558-45565, 2002. (Pubitemid 36159166)
34. Castro A, Arlot-Bonnemains Y, Vigneron S, Labbe JC, Prigent C and Lorca T: APC/Fizzy-Related targets Aurora-A kinase for proteolysis. EMBO Rep 3: 457-462, 2002. (Pubitemid 34567434)
35. Littlepage LE and Ruderman JV: Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev 16: 2274-2285, 2002. (Pubitemid 35013090)
36. Honda K, Mihara H, Kato Y, et al: Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 19: 2812-2819, 2000. (Pubitemid 30386417)
37. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A and Horii A: AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 25: 4831-4839, 2006. (Pubitemid 44201174)
38. Horiguchi A, Oya M, Marumo K and Murai M: STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int 61: 926-938, 2002. (Pubitemid 34175461)
39. Sen S, Zhou H and White RA: A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14: 2195-2200, 1997. (Pubitemid 27248231)
40. Tanner MM, Grenman S, Koul A, et al: Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 6: 1833-1839, 2000. (Pubitemid 30305079)
41. Sakakura C, Hagiwara A, Yasuoka R, et al: Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84: 824-831, 2001. (Pubitemid 32275658)
42. Hirata H, Hinoda Y, Matsuyama H, et al: Polymorphisms of DNA repair genes are associated with renal cell carcinoma. Biochem Biophys Res Commun 342: 1058-1062, 2006.
43. Cybulski C, Gorski B, Huzarski T, et al: CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75: 1131-1135, 2004. (Pubitemid 39532081)
44. Page T, Hodgkinson AD, Ollerenshaw M, Hammonds JC and Demaine AG: Glucose transporter polymorphisms are associated with clear-cell renal carcinoma. Cancer Genet Cytogenet 163: 151-155, 2005. (Pubitemid 41760412)
45. Yu J, Habuchi T, Tsuchiya N, et al: Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. J Urol 172: 2410-2413, 2004. (Pubitemid 39507545)
46. Sasaki M, Tanaka Y, Okino ST, et al: Polymorphisms of the CYP1B1 gene as risk factors for human renal cell cancer. Clin Cancer Res 10: 2015-2019, 2004. (Pubitemid 38375561)